Autopoiesis Sciences lands $11M seed to build autonomous AI scientist
What's the deal? Autopoiesis SciencesDealroom has a profile for this one. Try Dealroom →, a San Francisco startup building AI tools for scientific research, raised $11 million in seed funding led by Threshold Ventures. Informed VenturesDealroom has a profile for this one. Try Dealroom →, Alpaca VCDealroom has a profile for this one. Try Dealroom →, VitalStage VenturesDealroom has a profile for this one. Try Dealroom →, Correlation VenturesDealroom has a profile for this one. Try Dealroom →, and Darkmode VenturesDealroom has a profile for this one. Try Dealroom → also backed the round, announced September 30. The company declined to share its valuation.
What's the endgame? The money funds Aristotle, an AI system built to help researchers with literature reviews, hypothesis generation, and experimental design. Threshold partner Lisa Xu said the firm sees potential for "building AI capable of autonomously performing scientific discovery." Threshold claims Aristotle reaches thousands of researchers at Pfizer, the FDA, Harvard, GlaxoSmithKlineDealroom has a profile for this one. Try Dealroom →, MerckDealroom has a profile for this one. Try Dealroom →, and MIT.
Under the hood: Autopoiesis uses what Threshold calls Metacognitive Steering, which adjusts how a model reasons through multi-step investigations. The same architecture powers Columbus-1, an autonomous research system launched over the summer. In an August 2026 audit, security firm Xchg LabsDealroom has a profile for this one. Try Dealroom → said Columbus-1 found 21 defects in the Linux Bluetooth stack BlueZ 5.86 — eight of them zero-day vulnerabilities.
Who's behind it? Chief executive officer Joseph Reth leads the company with co-founders Eike Gerhardt and Lawrence Callahan. Callahan brings decades of experience at the FDA and NIH. This is Autopoiesis's second known raise, after an earlier undisclosed round led by Informed Ventures.
What could go wrong? The company has published no customer case studies or client logos, per Threshold's own post. Lab work still leans heavily on human intuition and domain expertise, and whether the technology handles the messier realities of bench science remains an open question.
The signal: The round lands as venture investors warm to AI-driven research automation — AutoscienceDealroom has a profile for this one. Try Dealroom → pulled in $14 million from General Catalyst in March. At $11 million, Autopoiesis sits in the top 4% of all US health seed rounds, well above the roughly $21.6 million median seed post-money valuation Carta tracked early this year. The test now is moving from demos to sustained use in working labs.
Read more: founderland.ai
Image credit: Autopoiesis Sciences
